Xenon Pharmaceuticals Smashes Its Previous Record High On ‘Unprecedented’ Results. Is A Buyout Next?

Xenon Pharmaceuticals (XENE) stock launched Monday, smashing its previous record high, on “unprecedented” results for its seizure treatment. The biotech company tested its daily pill, azetukalner, in patients with focal onset seizures. In this condition, partial seizures form in one area of the brain and generally last one to two minutes. A high dose of azetukalner lowered monthly seizures by…